Discovery and development of fully human monoclonal antibody drugs
Kymab has developed a proprietary mouse platform that contains the full range of human antibodies, leading to faster discovery of prophylactic and therapeutic monoclonal antibodies.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Exit
- Initial investment
- Series C
- Partnered in
- 2014
- Headquarters
- United Kingdom
- Portfolio news
- In 2021, Kymab was acquired by Sanofi
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.